Systematic review with meta-analysis: Cause-specific and all-cause mortality trends across different coeliac disease phenotypes.
Autor: | Maimaris S; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.; Gastroenterology Unit of Pavia Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Schiepatti A; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.; Gastroenterology Unit of Pavia Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Biagi F; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.; Gastroenterology Unit of Pavia Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy. |
---|---|
Jazyk: | angličtina |
Zdroj: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Mar; Vol. 59 (5), pp. 592-605. Date of Electronic Publication: 2024 Jan 11. |
DOI: | 10.1111/apt.17867 |
Abstrakt: | Background: Data on mortality in coeliac disease are contrasting. Aims: To systematically review the literature on all-cause and cause-specific mortality in coeliac disease compared to the general population, and evaluate differences across clinical phenotypes, geographical regions, and over time. Methods: We searched PubMed and Embase from 1 January 1970 to 31 December 2022 for eligible studies reporting on all-cause and cause-specific mortality in coeliac disease compared to the general population or controls. The protocol was registered on Open Science Framework (https://doi.org/10.17605/OSF.IO/852DN). Results: We included 25 studies. All-cause mortality (HR 1.16, 95% CI 1.05-1.27, I 2 = 89%), mortality due to malignancies (HR 1.21, 95% CI 1.08-1.36, I 2 = 65%) and respiratory disease (HR 1.39, 95% CI 1.04-1.86, I 2 = 76%) were increased. Mortality due to non-Hodgkin lymphoma (HR 10.14, 95% CI 2.19-46.88, I 2 = 96%) was markedly increased. Mortality significantly decreased in recent decades: 1989-2004 (HR 1.61, 95% CI 1.27-2.03, I 2 = 91%), 2005-2014 (HR 1.16, 95% CI 0.99-1.36, I 2 = 89%), 2015-2022 (HR 1.19, 95% CI 1.05-1.35, I 2 = 93%). All-cause mortality was not increased in dermatitis herpetiformis (HR 0.85, 95% CI 0.73-0.99, I 2 = 40%) and undiagnosed coeliac disease (HR 1.09, 95% CI 0.95-1.25, I 2 = 0%). Mortality was increased in the UK (HR 1.23, 95% CI 1.03-1.47, I 2 = 91%) but not Scandinavia (HR 1.01, 95% CI 0.91-1.13, I 2 = 81%). Limitations include high heterogeneity and lack of data for many countries. Conclusion: Mortality in coeliac disease is increased, predominantly due to malignancies-particularly non-Hodgkin lymphoma-although differing significantly across disease phenotypes. Mortality of patients with coeliac disease has significantly decreased in recent decades. These results may influence diagnosis and management. (© 2024 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |